Immunosenescence shapes the tumor immune microenvironment and limits PD-1/PD-L1 blockade efficacy in older patients with cancer
{{output}}
As the global population ages, immunosenescence is emerging as a critical determinant of cancer outcomes in older adults. Although programmed cell death protein 1/protein programmed death-ligand 1 (PD-1/PD-L1) blockade has significantly improved the treatment ... ...
